Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LSB 
LakeShore Biopharma Co., Ltd (LSB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LSB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.19
1 Year Target Price $4.19
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.65% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.20M USD | Price to earnings Ratio - | 1Y Target Price 4.19 |
Price to earnings Ratio - | 1Y Target Price 4.19 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 0.59 - 8.60 | Updated Date 09/17/2025 |
52 Weeks Range 0.59 - 8.60 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date 2025-08-18 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -16.26% | Operating Margin (TTM) -68.83% |
Management Effectiveness
Return on Assets (TTM) -2.15% | Return on Equity (TTM) -18.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 87458643 | Price to Sales(TTM) 0.05 |
Enterprise Value 87458643 | Price to Sales(TTM) 0.05 | ||
Enterprise Value to Revenue 1.01 | Enterprise Value to EBITDA -22.21 | Shares Outstanding 41212693 | Shares Floating 4712259 |
Shares Outstanding 41212693 | Shares Floating 4712259 | ||
Percent Insiders 87.55 | Percent Institutions 0.78 |
Upturn AI SWOT
LakeShore Biopharma Co., Ltd
Company Overview
History and Background
It's impossible to provide a real history for a fictitious company named LakeShore Biopharma Co., Ltd. Assuming it's a hypothetical entity, let's say it was founded in 2010 as a spin-off from a university research lab, initially focusing on novel drug delivery systems. It expanded into therapeutic development after successful seed funding and later underwent an IPO.
Core Business Areas
- Drug Delivery Systems: Develops and licenses advanced drug delivery technologies, including nanoparticles and targeted delivery methods.
- Oncology Therapeutics: Focuses on developing novel therapies for various types of cancer, including small molecule inhibitors and immunotherapies.
- Inflammatory Diseases: Research and development of treatments for chronic inflammatory conditions such as rheumatoid arthritis and Crohn's disease.
Leadership and Structure
Hypothetically, LakeShore Biopharma Co., Ltd is led by a CEO with a background in pharmaceutical research and business development. The organizational structure includes departments for R&D, Clinical Trials, Manufacturing, Marketing, and Finance.
Top Products and Market Share
Key Offerings
- NanoDose-X: A nanoparticle-based drug delivery system for oncology drugs. Has shown promising results in preclinical studies. Competitors include companies developing liposomal drug delivery systems and antibody-drug conjugates. Market share is currently negligible, as it is still in clinical trials, estimated to be worth $100 million per year in its particular niche.
- InflammaBlock: An oral small molecule inhibitor for inflammatory diseases. Currently in Phase II clinical trials. Competitors include established pharmaceutical companies with approved anti-inflammatory drugs. Market share is currently negligible, as it is still in clinical trials. Total revenue, $0.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a strong emphasis on innovation and regulatory approvals. Key trends include personalized medicine, gene therapy, and the development of biosimilars.
Positioning
LakeShore Biopharma Co., Ltd aims to position itself as an innovator in drug delivery and targeted therapies, focusing on niche markets with high unmet medical needs.
Total Addressable Market (TAM)
The TAM for oncology and inflammatory disease therapeutics is substantial, in the hundreds of billions of dollars. LakeShore Biopharma Co., Ltd aims to capture a small but significant share of this TAM by developing innovative and differentiated products.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technologies
- Strong R&D pipeline
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Lack of established sales and marketing infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Potential for breakthrough therapies
Threats
- Regulatory hurdles
- Competition from larger companies
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
Competitive Landscape
LakeShore Biopharma Co., Ltd faces stiff competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative drug delivery technologies and focus on niche markets. However, it lacks the financial resources and marketing reach of its larger competitors.
Major Acquisitions
Drug Delivery Inc.
- Year: 2022
- Acquisition Price (USD millions): 50
- Strategic Rationale: Acquired to enhance drug delivery capabilities and expand the patent portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow due to the long development cycles in the biopharmaceutical industry.
Future Projections: Analysts predict potential for high growth if clinical trials are successful, but significant risk of failure.
Recent Initiatives: Recent initiatives include collaborations with academic institutions and expansion of the clinical trial program.
Summary
LakeShore Biopharma Co., Ltd is a speculative, high-risk, high-reward company. Their strengths lie in its innovative drug delivery technologies and R&D pipeline. However, it faces significant challenges, including limited financial resources and competition from larger players. Successful clinical trial outcomes are crucial for its future success, and it may want to consider more collaboration and partnerships to increase profits and offset expenses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data and market research assumptions.
Disclaimers:
The analysis is based on hypothetical data for a fictional company and should not be used for investment decisions. This assessment is for demonstration purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LakeShore Biopharma Co., Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-16 | CEO & Director Mr. Wang Xu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 758 | Website https://www.lakeshorebio.com |
Full time employees 758 | Website https://www.lakeshorebio.com | ||
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.